Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.
Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M. · 2019
Read Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. by Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6889286.txt.
Description
Leonetti and co-authors review resistance to a leading lung cancer drug, in the British Journal of Cancer. Osimertinib blocks the epidermal growth factor receptor in its mutated forms, including the T790M form that defeats older drugs. It works in advanced non-small cell lung cancer driven by such mutations. Every patient, though, eventually develops resistance. Clear next options are then lacking.
The review sorts resistance into changes within the target gene and detours around it. A further mutation, C797S, can lock the drug out; rarer swaps such as L718Q answer to older drugs instead. Other tumours wake side pathways or change cell type entirely. Blood tests for tumour DNA help track which route a given cancer took.
Catalog record
| CREATOR | Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 77 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |